White House unveils next round of MFN pricing deals with 9 midsized drugmakers

Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top players, the U.S. | Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top players, the U.S. government is back for round 2, this time lining up agreements with a host of medium-sized biopharmas under President Trump’s ‘most favored nation’ agenda.